You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Details for New Drug Application (NDA): 208175


✉ Email this page to a colleague

« Back to Dashboard


NDA 208175 describes PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE, which is a drug marketed by Actavis Labs Fl Inc and Dr Reddys Labs Sa and is included in two NDAs. It is available from two suppliers. Additional details are available on the PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE profile page.

The generic ingredient in PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE is phentermine hydrochloride; topiramate. There are seventeen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride; topiramate profile page.
Summary for 208175
Suppliers and Packaging for NDA: 208175
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 208175 ANDA Dr.Reddys Laboratories Inc 43598-624 43598-624-30 30 CAPSULE in 1 BOTTLE (43598-624-30)
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE phentermine hydrochloride; topiramate CAPSULE, EXTENDED RELEASE;ORAL 208175 ANDA Dr.Reddys Laboratories Inc 43598-625 43598-625-30 30 CAPSULE in 1 BOTTLE (43598-625-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 3.75MG BASE;23MG
Approval Date:Jun 12, 2025TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 7.5MG BASE;46MG
Approval Date:Jun 12, 2025TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 11.25MG BASE;69MG
Approval Date:Jun 12, 2025TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.